Health Wizz — pivoted away from patient-data-sovereignty, re-scored 0/3
Verdict (one line)
Pivoted away. Health Wizz's 2026 product is clinical-trial-recruitment B2B SaaS for pharma sponsors and CROs (Journey Wizz platform, FHIR-via-150-EHRs integration). The original patient-as-filing-cabinet + data-broker model that earned a 1.5/3 score on the May 11 scan is gone from the live product surface — replaced by a polished pharma-trial-recruitment pitch with named metrics (60% screen-failure reduction, 3x site activation). Re-score: 0/3 on the patient-data-sovereignty + outcome-procurement wedge. Same pivot pattern as Hu-manity.co — patient-sovereignty rhetoric collapsed into a different revenue model when the sovereignty thesis couldn't generate revenue.
The question
Health Wizz status check — re-score against the 3-leg (Data-Sovereignty + Value-Based-Contract + Patient-Incentive cash) rubric from the May 11 patient-data-sovereignty competitor scan. Need to confirm whether Health Wizz is still a 2026 competitor on the wedge or whether it joins Hu-manity in the pivoted-away cautionary-tale bucket.
What we already know (from the vault)
- [[2026-05-11-patient-data-sovereignty-competitor-scan]] — Health Wizz originally scored 1.5/3: DS partial (patient holds + bundles their own data), VBC: NO, PI partial (sold data to pharma/research with some revenue share to patient). Same shape category as Embleema (data-broker patient-payouts). Verdict: data-broker model, not care-economics model. Not on the wedge but adjacent.
- [[2026-05-18-hu-manity-co-zombie-status]] — Hu-manity rescored from 1.5/3 to 0/3 after the May 18 follow-up. Pattern documented: patient-data-sovereignty rhetoric without payer-side / outcomes-side revenue mechanism collapses into a different SaaS product (cookie/consent compliance in Hu-manity's case). Question for this brief: did Health Wizz follow the same pattern?
- [[2026-05-18-cms-access-approved-applicant-roster]] — Health Wizz was NOT in the named subset of CMS ACCESS Model approved applicants. Consistent with not pursuing the patient-sovereignty + VBC bundle in 2026.
What the web says
- Live product (2026): healthwizz.com landing pitch is clinical-trial-recruitment automation. Core claims: "connects securely to 150+ EHR systems via FHIR APIs — automatically matching eligible patients to your open trials." Named metrics: 60% reduction in screen failures, 3x faster site activation, zero new IT infrastructure required. Buyer: pharma sponsors, CROs, research sites — B2B pharma, not direct-to-patient (healthwizz.com WebFetch 2026-05-24).
- Journey Wizz platform extension: Tracxn / Crunchbase profiles describe Journey Wizz as an "advanced platform that automates social media campaigns and provides critical data insights to optimize clinical trial performance" — same pharma-trial-recruitment vertical, marketing-automation layer added (Tracxn Health Wizz 2026 profile).
- Funding stagnation: Total raised $737K, last round Seed Jan 15, 2018. No follow-on rounds in 8 years (Crunchbase Health Wizz).
- Team size: 3 employees as of March 31, 2026 (Tracxn 2026 profile). Hu-manity sits at 20 employees in the same bucket; Health Wizz is much smaller.
- Patient-app residual: The Health Wizz iOS app remains live on the App Store (App Store listing). Marketing copy still claims "users have complete control over who gets to see what part of their health data and for how long" — same patient-sovereignty rhetoric as 2018-launch. The patient app is the residual zombie surface; the commercial product is the trial-recruitment platform.
- Recent partnership: Strategic partnership + new research center with Prime Healthcare and EmVenio Research — operationally alive but pointed at the clinical-trial-recruitment vertical, not patient-sovereignty.
- Activity signals: Zero dated press releases or blog posts visible on healthwizz.com homepage. Copyright year 2026 is a template artifact, not evidence of recent activity. Polished pitch + absence of named customers / pricing / press dates suggests a small-team operation with intermittent updates.
Convergences and contradictions
- Convergence: Vault scoring (1.5/3 May 11, data-broker shape) + web evidence (current product = clinical-trial-recruitment B2B pharma) agree Health Wizz is NOT on the patient-data-sovereignty + outcome-procurement wedge in 2026. The May 11 scoring already recognized this directionally; the 2026 product confirms the pivot is mechanical.
- Convergence with Hu-manity pattern: Same shape as the Hu-manity zombie pattern — patient-sovereignty marketing rhetoric persists at the legacy app + about-page level, but the commercial product has pivoted to a different B2B vertical with revenue mechanism. Health Wizz chose pharma trial recruitment; Hu-manity chose cookie/consent SaaS. Both abandoned the "patient owns data, patient gets paid for it" thesis when revenue didn't materialize.
- Contradiction with May 11 baseline: The DS-partial + PI-partial scoring on May 11 was based on the patient-app surface (filing cabinet + data-sale revenue share). The web evidence shows the patient-app revenue model is no longer the company's commercial focus — Journey Wizz and the pharma-trial-recruitment B2B is. Therefore DS-partial + PI-partial should drop to 0/3 because the actual revenue product is pharma-trial-recruitment infrastructure, with the patient as recruitment target, not principal.
- Cross-check vs CMS ACCESS: Health Wizz didn't apply to CMS ACCESS (per May 18 roster). If they were still positioning as a patient-sovereignty-meets-VBC play in 2026, ACCESS Model would have been an obvious surface — they didn't go there, which corroborates the pivot.
Synthesis for RDCO
The May 11 scan's "clean white space" verdict gets stronger, not weaker. Two of the three 1.5/3-to-2/3 "closest competitors" (Hu-manity and Health Wizz) are now confirmed-pivoted-away in May 2026. That leaves Embleema (2/3 in form) as the only remaining serious competitor on the wedge — and the May 22 Embleema brief showed they pivoted to DoD biosecurity, not VBC + patient-sovereignty. The patient-data-sovereignty + outcome-procurement wedge is now even cleaner than the May 11 verdict claimed — all three "closest competitor" candidates have functionally abandoned the thesis.
The failure-mode pattern is now repeatable enough to name. Both Hu-manity and Health Wizz built (a) patient-anchored data-rights/sovereignty rhetoric, (b) a patient-facing app to hold the data, and (c) an aspirational data-licensing-revenue-share model. Both stalled at sub-$1M funding (Health Wizz $737K, Hu-manity $5.5M pre-seed). Both pivoted into a different B2B vertical where revenue is real (trial recruitment / cookie compliance), keeping the patient-sovereignty marketing copy as legacy branding. The pattern: patient-sovereignty + data-licensing-as-revenue does not stand alone as a commercial wedge — the operator either pivots to a B2B vertical or stalls. This is why the May 11 bet architecture requires the VBC + outcomes-tied PI legs together — without the contracted-savings flow, the patient-sovereignty leg has no sustainable revenue model.
Specific RDCO action: In the Phase-1 MVP positioning copy, cite Hu-manity and Health Wizz as the cautionary-tale duo — both as social proof that "patient app + data licensing revenue share" alone has been tried twice and failed twice, validating the structural choice to bundle DS with VBC + outcomes-PI. This becomes a defensible differentiation paragraph in the bet-architecture v2 and a candidate Sanity Check editorial angle ("the two times patient-data sovereignty got tried as a standalone business model in the last 8 years, here's where they ended up").
The pivot-pattern also informs the kill criteria for RDCO's own bet. If after 18 months the VBC + PI legs cannot generate contracted revenue and only the patient-app DS leg is operationally alive, the RDCO bet has hit the same failure mode as Hu-manity and Health Wizz — at which point the kill-or-pivot decision should NOT be "lean into the patient-app and find a different B2B vertical" (that's the trap both predecessors fell into). It should be a clean wind-down.
Open follow-ups
- Embleema status check (already filed 2026-05-22) plus the residual biosecurity GRAVL/ANTIDOTE check (Notion Inbox, Low priority) — confirmed the third candidate also pivoted away. The full competitor-scan close-out is the next /investing or /process-inbox candidate.
- Has any 2024-2026 startup attempted the patient-sovereignty + VBC + PI bundle and NOT yet shown up in the May 11 scan? Stealth-mode CMS ACCESS cohort-1 participant disclosure could surface a new candidate. Re-run a competitor-scan when the cohort-1 participant list publishes (probably Q3 2026).
- Health Wizz Journey Wizz vs. larger trial-recruitment incumbents (TrialBee, Antidote, Inato) — at 3 employees and $737K total raised, what's Health Wizz's actual win rate vs. better-capitalized pharma-trial-recruitment players? Probably losing, but a sponsor-side data point would confirm Health Wizz is on a glide path to acquihire or shutdown within 24 months.
- The failure-mode pattern "patient-sovereignty + data-licensing-revenue-share alone collapses to a different B2B vertical" — does it hold for any non-US analogs? European GDPR consent-management vendors (OneTrust, Cookiebot) include former patient-data-rights operators that took the same exit path. Worth a brief if a Sanity Check editorial pivots toward the failure-pattern angle.
- Does the residual Health Wizz iOS app + the Hu-manity Privacy Experience product expose any patient-PII risk surface that's interesting from a regulatory / acquihire-target perspective? Probably not load-bearing, but worth a 30-min check if the bet's regulatory-risk register needs more named-precedent material.
Sources
Vault:
- [[2026-05-11-patient-data-sovereignty-competitor-scan]] (parent scan, original 1.5/3 scoring)
- [[2026-05-18-hu-manity-co-zombie-status]] (companion, same pattern, rescored 0/3)
- [[2026-05-18-cms-access-approved-applicant-roster]] (cross-check: Health Wizz absent)
~/rdco-vault/01-projects/health-and-longevity/2026-05-10-data-sovereignty-outcome-procurement-bet-architecture.md(parent bet)
Web (accessed 2026-05-24):
- healthwizz.com — current product pitch (clinical trial recruitment)
- Health Wizz Tracxn 2026 profile — 3-employee headcount, funding history
- Health Wizz Crunchbase profile — $737K total raised, last Seed Jan 2018
- Health Wizz CB Insights profile
- Health Wizz App Store listing — legacy patient-app surface
- Health Wizz LinkedIn